ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,420.37
0.06%
Dow Jones
39,431.51
-0.21%
Gold vs US Dollar
2,346.24
0.31%
Brent Oil
83.14
-0.08%
Bitcoin
61,651.39
-1.99%
Pepperstone
Advertisement
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NYSE
  6. Takeda Pharmaceutical Company Ltd (TAK)

  7. Takeda Pharmaceutical Company Ltd (TAK) News

Takeda Pharmaceutical (TAK)

Takeda Pharmaceutical Company Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:NYSE:TAK
DateTimeSourceHeadlineSymbolCompany
10/05/202412:03Business WireTakeda annonce ses résultats pour l’exercice 2023 et ses perspectives pour l’exercice 2024, confirmant son engagement en faveur du développement d’un portefeuille de produits à un stade avancé et de l’augmentation de la marge bénéficiaire...NYSE:TAKTakeda Pharmaceutical Company Ltd
09/05/202422:07Business WireTakeda veröffentlicht Ergebnisse für das Geschäftsjahr 2023, liefert Ausblick auf das GJ 2024, und bekräftigt Bekenntnis zur Pipeline-Entwicklung in der späten Entwicklungsphase sowie zur Steigerung der operativen GewinnmargeNYSE:TAKTakeda Pharmaceutical Company Ltd
09/05/202407:07Business Wire武田薬品工業: 2023年度通期業績および2024年度の見通しを公表 - 後期段階のパイプライン開発とCore営業利益率改善へのコミットメントを強調NYSE:TAKTakeda Pharmaceutical Company Ltd
09/05/202407:07Business WireTakeda Announces FY2023 Full Year Results and FY2024 Outlook, Affirming Commitment to Late-Stage Pipeline Development and Core Operating Profit Margin ExpansionNYSE:TAKTakeda Pharmaceutical Company Ltd
26/04/202413:30Business WireTakeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal CancerNYSE:TAKTakeda Pharmaceutical Company Ltd
26/04/202413:30GlobeNewswire Inc.HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by TakedaNYSE:TAKTakeda Pharmaceutical Company Ltd
23/04/202412:00PR Newswire (US)Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive DisorderNYSE:TAKTakeda Pharmaceutical Company Ltd
22/04/202409:10PR Newswire (US)Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery ProgramsNYSE:TAKTakeda Pharmaceutical Company Ltd
19/04/202400:00Business WireU.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s DiseaseNYSE:TAKTakeda Pharmaceutical Company Ltd
08/04/202413:00Business WireTakeda Announces New U.S. Corporate Social Responsibility Program Partners to Build Equity through STEM Education and Access to Nutritional FoodNYSE:TAKTakeda Pharmaceutical Company Ltd
27/03/202412:56PR Newswire (US)Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAENYSE:TAKTakeda Pharmaceutical Company Ltd
27/03/202412:53PR Newswire (US)Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAENYSE:TAKTakeda Pharmaceutical Company Ltd
27/03/202405:01Business WireTakeda gibt Kandidaten für den Vorstand bei der kommenden Aktionärsversammlung bekanntNYSE:TAKTakeda Pharmaceutical Company Ltd
27/03/202405:01Business WireTakeda annonce les candidats au conseil d’administration pour la prochaine assemblée générale des actionnairesNYSE:TAKTakeda Pharmaceutical Company Ltd
26/03/202423:07Business WireTakeda Announces Candidates for Board of Directors at Upcoming Shareholders MeetingNYSE:TAKTakeda Pharmaceutical Company Ltd
26/03/202423:07Business Wire武田薬品工業: 第148回定時株主総会に提案する取締役候補者についてNYSE:TAKTakeda Pharmaceutical Company Ltd
26/03/202412:00Business WireTakeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)NYSE:TAKTakeda Pharmaceutical Company Ltd
21/03/202413:39Business Wire武田薬品、Ph+ ALLの初発成人患者に対するアイクルシグ®（ポナチニブ）の医薬品承認事項変更申請（sNDA）について、FDAからの承認取得を発表NYSE:TAKTakeda Pharmaceutical Company Ltd
21/03/202407:33Business WireTakeda meldet sNDA-Zulassung von ICLUSIG® (Ponatinib) durch die FDA bei erwachsenen Patienten mit neu diagnostizierter Ph+ ALLNYSE:TAKTakeda Pharmaceutical Company Ltd
20/03/202419:18Business WireTakeda annonce l'approbation par la FDA des États-Unis d'une demande supplémentaire de nouveau médicament (sNDA) pour ICLUSIG ® (ponatinib) chez les patients adultes atteints de leucémie lymphoblastique aiguë (LAL Ph+) nouvellement diagnostiquéeNYSE:TAKTakeda Pharmaceutical Company Ltd
19/03/202416:20Business WireTakeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALLNYSE:TAKTakeda Pharmaceutical Company Ltd
19/03/202410:30GlobeNewswire Inc.CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage DisordersNYSE:TAKTakeda Pharmaceutical Company Ltd
13/03/202412:00Business WireTakeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune ThrombocytopeniaNYSE:TAKTakeda Pharmaceutical Company Ltd
28/02/202412:03Business Wire武田薬品とBiological E. Limited、デング熱流行地域におけるワクチンへのアクセス促進で協力NYSE:TAKTakeda Pharmaceutical Company Ltd
27/02/202422:26Business WireTakeda et Biological E. Limited s’associent pour accélérer l’accès au vaccin contre la dengue dans les zones endémiquesNYSE:TAKTakeda Pharmaceutical Company Ltd
27/02/202412:38Business WireTakeda und Biological E. Limited arbeiten zusammen, um den Zugang zu Dengue-Impfstoff in endemischen Gebieten zu beschleunigenNYSE:TAKTakeda Pharmaceutical Company Ltd
27/02/202404:30Business WireTakeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic AreasNYSE:TAKTakeda Pharmaceutical Company Ltd
26/02/202412:00PR Newswire (Canada)Championing Rare Voices on Rare Disease DayNYSE:TAKTakeda Pharmaceutical Company Ltd
26/02/202412:00PR Newswire (Canada)Faire entendre sa voix à l'occasion de la Journée des maladies raresNYSE:TAKTakeda Pharmaceutical Company Ltd
12/02/202413:00Business WireFDA Approves Takeda’s EOHILIA (budesonide oral suspension), the First and Only Oral Treatment in the U.S. for Eosinophilic Esophagitis (EoE)NYSE:TAKTakeda Pharmaceutical Company Ltd
 Showing the most relevant articles for your search:NYSE:TAK

Your Recent History

LSE
SOLG
Solgold
LSE
BIRD
Blackbird
LSE
TXP
Touchstone Exploration
LSE
GDR
Genedrive
LSE
VOD
Vodafone
LSE
PANR
Pantheon Resources
LSE
OTB
On The Beach
LSE
AAZ
Anglo Asian Mining
LSE
EEE
Empire Metals
LSE
BOO
Boohoo
LSE
ENET
Ethernity Networks
LSE
ARS
Asiamet Resources
LSE
TERN
Tern
LSE
OPG
Opg Power Ventures
LSE
VRS
Versarien
LSE
PET
Petrel Resources
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved